These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Complement factor H: using atomic resolution structure to illuminate disease mechanisms. Barlow PN; Hageman GS; Lea SM Adv Exp Med Biol; 2008; 632():117-42. PubMed ID: 19025119 [TBL] [Abstract][Full Text] [Related]
4. Transcriptional regulation of porcine endogenous retroviruses released from porcine and infected human cells by heterotrimeric protein complex NF-Y and impact of immunosuppressive drugs. Scheef G; Fischer N; Flory E; Schmitt I; Tönjes RR J Virol; 2002 Dec; 76(24):12553-63. PubMed ID: 12438581 [TBL] [Abstract][Full Text] [Related]
5. Farming for spare body parts: silk purse or sow's ear. Atkinson JP Trans Am Clin Climatol Assoc; 2001; 112():14-25; discussion 26. PubMed ID: 11413773 [No Abstract] [Full Text] [Related]
6. GluR3 autoantibodies destroy neural cells in a complement-dependent manner modulated by complement regulatory proteins. Whitney KD; McNamara JO J Neurosci; 2000 Oct; 20(19):7307-16. PubMed ID: 11007888 [TBL] [Abstract][Full Text] [Related]
7. Establishment and characterization of molecular clones of porcine endogenous retroviruses replicating on human cells. Czauderna F; Fischer N; Boller K; Kurth R; Tönjes RR J Virol; 2000 May; 74(9):4028-38. PubMed ID: 10756014 [TBL] [Abstract][Full Text] [Related]
8. Effect of a platelet-activating factor (PAF) receptor antagonist on hyperacute xenograft rejection; evaluation in a pig kidney-human blood xenoperfusion model. Cruzado JM; Torras J; Riera M; Lloberas N; Herrero I; Condom E; Martorell J; Alsina J; Grinyó JM Clin Exp Immunol; 1998 Jul; 113(1):136-44. PubMed ID: 9697996 [TBL] [Abstract][Full Text] [Related]
9. The future use of complement inhibitors for the treatment of neurological diseases. McGeer EG; McGeer PL Drugs; 1998 Jun; 55(6):739-46. PubMed ID: 9617589 [TBL] [Abstract][Full Text] [Related]
10. Mutational analysis of the active site and antibody epitopes of the complement-inhibitory glycoprotein, CD59. Bodian DL; Davis SJ; Morgan BP; Rushmere NK J Exp Med; 1997 Feb; 185(3):507-16. PubMed ID: 9053451 [TBL] [Abstract][Full Text] [Related]
11. The generation of transgenic pigs as potential organ donors for humans. Cozzi E; White DJ Nat Med; 1995 Sep; 1(9):964-6. PubMed ID: 7585226 [No Abstract] [Full Text] [Related]
12. Complement inhibition with an anti-C5 monoclonal antibody prevents hyperacute rejection in a xenograft heart transplantation model. Wang H; Rollins SA; Gao Z; Garcia B; Zhang Z; Xing J; Li L; Kellersmann R; Matis LA; Zhong R Transplantation; 1999 Dec; 68(11):1643-51. PubMed ID: 10609940 [TBL] [Abstract][Full Text] [Related]
13. Current status of xenotransplantation. Wallwork J Int J Cardiol; 1997 Dec; 62 Suppl 1():S37-8. PubMed ID: 9464581 [No Abstract] [Full Text] [Related]
14. Complement inhibitory therapeutics and xenotransplantation. Ryan US Nat Med; 1995 Sep; 1(9):967-8. PubMed ID: 7585227 [TBL] [Abstract][Full Text] [Related]
15. The effect of soluble complement receptor type 1 on acute humoral xenograft rejection in hDAF-transgenic pig-to-primate life-supporting kidney xenografts. Lam TT; Hausen B; Hook L; Lau M; Higgins J; Christians U; Jacobsen W; Baluom M; Duthaler R; Katopodis A; Chavez G; Cozzi E; Harrison R; Schuurman HJ; Borie D; Morris RE Xenotransplantation; 2005 Jan; 12(1):20-9. PubMed ID: 15598270 [TBL] [Abstract][Full Text] [Related]
16. Inhibition of complement, evoked antibody, and cellular response prevents rejection of pig-to-primate cardiac xenografts. Davis EA; Pruitt SK; Greene PS; Ibrahim S; Lam TT; Levin JL; Baldwin WM; Sanfilippo F Transplantation; 1996 Oct; 62(7):1018-23. PubMed ID: 8878398 [TBL] [Abstract][Full Text] [Related]